Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge.
On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)’s weight-loss pill Foundayo for both weight management and type 2 diabetes, making the UK the first country in Europe to approve the drug.
Why Two Drugmakers Chose Different Battlegrounds
Bristol-Myers Squibb Company (NYSE:BMY)’s new Houston campus, roughly 600,000 square feet, will churn out everything from small-molecule medicines to more complex biologics and antibody-drug conjugates. It is expected to create close to 500 skilled jobs and about 2,000 construction jobs between 2027 and 2030. CEO Christopher Boerner framed it as a vote of confidence in America’s biopharma future. The timing lines up with a broader industry trend: drugmakers from Lilly to Johnson & Johnson to Pfizer are all racing to build more in the U.S. as tariff pressure from the Trump administration ramps up.
Eli Lilly took the opposite direction this week, expanding outward instead of inward. Foundayo’s UK approval opens a major new market, even though the pill isn’t covered by the National Health Service yet and still trails Novo Nordisk’s Wegovy pill there.
So which strategy actually serves shareholders better, building strength at home or chasing growth abroad?
Bristol Myers’s Bull and Bear Case
The Houston investment folds neatly into Bristol’s larger $40 billion U.S. buildout, and it comes at a moment when tariff exposure is a genuine worry across the industry. Texas is making the offer even more attractive by giving them $4.89 million in state funding.
Still, a new factory doesn’t fix Bristol’s real problem. Two of Bristol-Myers Squibb Company (NYSE:BMY)’s best-selling drugs, Eliquis and Opdivo, will soon lose their patent protection. No amount of domestic manufacturing capacity replaces that lost revenue on its own.
Eli Lilly’s Bull and Bear Case
The UK nod extends Eli Lilly and Company (NYSE:LLY)’s already dominant obesity franchise into a new market. In the U.S. alone, Lilly controls 60.9% of the obesity and diabetes drug market to Novo Nordisk’s 38.8%, according to Lilly’s second-quarter results.
The problem is timing. Foundayo arrives in the UK well behind Novo’s Wegovy pill, and without NHS reimbursement, its near-term impact on Lilly’s UK sales looks modest at best.
Insider Monkey’s Hedge Fund Data
Insider Monkey’s hedge fund database tells a mixed story here. Bristol-Myers Squibb Company (NYSE:BMY) actually gained a bit of hedge fund interest, with 83 holders as of Q1 2026, up from 82 the quarter before. Eli Lilly went the other way, dropping to 132 holders from 137, with the dollar value hedge funds held in the stock falling from about $14.9 billion to $12.6 billion. Pfizer, another major pharma peer, held steady at 83 holders.
Conclusion
Bristol Myers is focusing on growing its business in its home market (the US) for the long term, while Eli Lilly continues to succeed in international markets due to its popular weight-loss drugs. Both moves signal confidence; they’re just pointed in opposite directions.
Overall, hedge funds favor Eli Lilly and Company (NYSE:LLY) over Bristol Myers.
While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk and Hedge Funds are Bullish on AstraZeneca PLC (AZN).
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center